Fosun Wanbang Pharma Group
Subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (600196) · China
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | IL-17AMonoclonal antibody | Psoriasis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
5 December 2025Filing acceptedRoconkibartNMPA accepts the roconkibart marketing application in plaque psoriasis
CN, NMPA · Shanghai Junshi Bioscience · Source ↗
Financial reports
No financial reports recorded.